RCS - OptiBiotix Health - Launch of products on Amazon India

OptiBiotix HealthAnnouncement

20/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250120:nRST8336Ta&default-theme=true

RNS Number : 8336T  OptiBiotix Health PLC  20 January 2025

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Launch of products on Amazon India

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare,
announces the launch of multiple SlimBiome® containing products under
OptiBiotix's GoFigure® brand on Amazon India.

 

India is already the most populous nation on Earth, anticipated to have the
world's largest cohort of medium to high level income consumers by 2035. With
obesity prevalence currently measured at 40.3%, India represents a huge area
of opportunity for weight management products.

 

OptiBiotix's wholly owned subsidiary, OptiBiotix India, will sell GoFigure®
products via Amazon and continue to sell in store through Apollo Pharmacies
and Apollo's own website across India as part of a multi-channel approach.
Launching meal replacement and flavoured shots on Amazon India is part of a
planned strategy to invest in high growth markets and increase final product
sales to customers through ecommerce channels. This multichannel approach
complements our core business-to-business activities by raising the awareness
of SlimBiome® containing products across multiple channels and partners.

 

The Amazon India launch has coincided with a rebrand of packaging and relaunch
with Apollo pharmacies. The new packaging is more colourful allowing it to
stand out and Tata's Fossence(®) branding is more prominent on pack. The
Gofigure(®) products are made in India by local manufacturers and include
ingredients such as Tata's proprietary Fossence(®) which bring the assurance
and familiarity of a branded ingredient from a well-known and respected local
source to the attention of Indian consumers.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "Launching products on Amazon
India is another step forward in building a presence for the Company's
products in the strategically important Indian market. We are now building
SlimBiome's® presence across India via our own brand products through Amazon
India and via Apollo pharmacies, and as private label partnerships following
the recent launch by Dr Morepen. This initial launch will include four
products with subsequent launches taking place throughout 2025 dependent on
sales progress."

 

The Directors of the Company are responsible for the release of this
announcement.

 

  For further information, please contact:

 

 OptiBiotix Health plc                        www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Peterhouse Capital Limited (Broker)          Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                              Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUBVVRVAUAAAR